Tags:BioTechDrugInvestmentPharmacy
June 2018, Series B Attune is a clinical-stage biotechnology company focused on novel small-molecule therapeutics for rare diseases. Attune's lead drug is in clinical trials for the treatment of HAE and a second program is focused on complement-mediated diseases. Investors include Venrock, RTW Investments, RA Capital, Tavistock and Tang Capital.

Investors 1

Mentions in press and media 3

DateTitleDescriptionCategoryAuthorSource
24.01.2019Attune Pha...Attune Pharmaceuticals, Inc., ...USA-finsmes.co...
23.01.2019Term Sheet...CRYPTO CAPITAL Good morning, ...--fortune.co...
23.01.2019Daily fund...AnChain.ai raised $2M; Chowbus...-Kristin Ka...vator.tv/n...